A review of 65 years of human adenovirus seroprevalence

References

• Ghebremedhin B. Human adenovirus: viral pathogen with increasing importance. Eur J Microbiol Immunol (Bp). 2014;4:26–33.
   PubMedGoogle Scholar
• Smith RR, Huebner RJ, Rowe WP, et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9:1211–1218.
   PubMed Web of Science ®Google Scholar
• Georgiades J, Zielinski T, Cicholska A, et al. Research on the oncolytic effect of APC viruses in cancer of the cervix uteri; preliminary report. Biul Inst Med Morsk Gdansk. 1959;10:49–57.
   PubMedGoogle Scholar
• Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy., adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013;13(13):421,421–433.
   PubMedGoogle Scholar
• Hillgenberg M, Tonnies H, Strauss M. Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-Kilobase genomic stuffer. J Virol. 2001;75:9896–9908.
   PubMed Web of Science ®Google Scholar
• Harmon AW, Byrnes AP. Adenovirus vector toxicity. In: Brunetti-Pierri N, editor. Safety and efficacy of gene-based therapeutics for inherited disorders. Cham, Switzerland: Springer Nature; 2017. p. 37–60.
   Google Scholar
• Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what’s important?. Hum Vaccin Immunother. 2014;10:2875–2884.
   PubMed Web of Science ®Google Scholar
• Berk AJ. Adenoviridae. In: Knipe DM and Howley PM, editors. Fields virology. 6th Edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. Vol. 2, p. 1704–1731.
   Google Scholar
• Van Oostrum J, Burnett RM. Molecular composition of the adenovirus type 2 virion. J Virol. 1985;56:439–448.
   PubMed Web of Science ®Google Scholar
• Rowe WP, Huebner RJ, Gilmore LK, et al. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Society for Experimental Biology and Medicine. 1953;84:570–573.
   Google Scholar
• Khanal S, Ghimire P, Dhamoon A. The repertoire of adenovirus in human disease: the innocuous to the deadly. Biomedicines. 2018;6:30.
   Web of Science ®Google Scholar
• Cooper RJ, Hallett R, Tullo AB, et al. The epidemiology of adenovirus infections in Greater Manchester, UK 1982–96. Epidemiol Infect. 2000;125:333–345.
   PubMed Web of Science ®Google Scholar
• Cebey-López M, Herberg J, Pardo-Seco J, et al. viral co-infections in pediatric patients hospitalized with lower tract acute respiratory infections. PLoS ONE. 2015;10:e0136526.
   PubMed Web of Science ®Google Scholar
• Esposito S, Zampiero A, Bianchini S, et al. Epidemiology and clinical characteristics of respiratory infections due to adenovirus in children living in Milan, Italy, during 2013 and 2014. PLoS ONE. 2016;11:e0152375.
   PubMed Web of Science ®Google Scholar
• Liu C, Xiao Y, Zhang J, et al. Adenovirus infection in children with acute lower respiratory tract infections in Beijing, China, 2007 to 2012. BMC Infect Dis. 2015;15.
   PubMed Web of Science ®Google Scholar
• Fischer TK, Rungoe C, Jensen CS, et al. The burden of rotavirus disease in Denmark 2009–2010. Pediatr Infect Dis J. 2011;30:e126–e129.
   PubMed Web of Science ®Google Scholar
• Fletcher S, Sibbritt D, Stark D, et al. Descriptive epidemiology of infectious gastrointestinal illnesses in Sydney, Australia, 2007–2010. West Pac Surveillance Response J. 2015;6:7–16.
   PubMedGoogle Scholar
• Lion T. Adenovirus Infections in Immunocompetent and Immunocompromised Patients. Clin Microbiol Rev. 2014;27:441–462.
   PubMed Web of Science ®Google Scholar
• Veltrop-Duits LA, van Vreeswijk T, Heemskerk B, et al. High titers of pre-existing adenovirus serotype-specific neutralizing antibodies in the host predict viral reactivation after allogeneic stem cell transplantation in children. Clinl Infect Dis. 2011;52:1405–1413.
   PubMed Web of Science ®Google Scholar
• Radin JM, Hawksworth AW, Blair PJ, et al. Dramatic decline of respiratory illness among us military recruits after the renewed use of adenovirus vaccines. Clinl Infect Dis. 2014;59:962–968.
   PubMed Web of Science ®Google Scholar
• Kuschner RA, Russell KL, Abuja M, et al. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits. Vaccine. 2013;31:2963–2971.
   PubMed Web of Science ®Google Scholar
• Choudhry A, Mathena J, Albano JD, et al. Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits. Vaccine. 2016;34:4558–4564.
   PubMed Web of Science ®Google Scholar
• Lin K-H, Lin Y-C, Chen H-L, et al. A two decade survey of respiratory adenovirus in Taiwan: the reemergence of adenovirus types 7 and 4. J Med Virol. 2004;73:274–279.
   PubMed Web of Science ®Google Scholar
• Lynch J, Fishbein M, Echavarria M. Adenovirus. Seminars in Respiratory and Critical Care Medicine. 2011;32:494–511.
   Google Scholar
• Zhang L, Zhao N, Sha J, et al. Virology and epidemiology analyses of global adenovirus-associated conjunctivitis outbreaks, 1953–2013. Epidemiol Infect. 2016;144:1661–1672.
   PubMed Web of Science ®Google Scholar
• Abbas KZ, Lombos E, Duvvuri VR, et al. Temporal changes in respiratory adenovirus serotypes circulating in the greater Toronto area, Ontario, during December 2008 to April 2010. Virol J. 2013;10:15.
   PubMed Web of Science ®Google Scholar
• Rosen L. A hemagglutination-inhibition technique for typing adenoviruses. Am J Hyg. 1960;71:120–128.
   PubMed Web of Science ®Google Scholar
• Ebner K, Pinsker W, Lion T. Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications. J Virol. 2005;79:12635–12642.
   PubMed Web of Science ®Google Scholar
• Gerd Liebert U, Bergs S, Ganzenmueller T, et al. Human mastadenovirus type 70: a novel, multiple recombinant species D mastadenovirus isolated from diarrhoeal faeces of a haematopoietic stem cell transplantation recipient. J Gen Virol. 2015;96:2734–2742.
   PubMed Web of Science ®Google Scholar
• Jones MS, Harrach B, Ganac RD, et al. New adenovirus species found in a patient presenting with gastroenteritis. J Virol. 2007;81:5978–5984.
   PubMed Web of Science ®Google Scholar
• Huang G-H, Xu W-B. Recent advance in new types of human adenovirus. Bing Du Xue Bao. 2013;29:342–348.
   PubMedGoogle Scholar
• Walsh MP, Chintakuntlawar A, Robinson CM, et al. evidence of molecular evolution driven by recombination events influencing tropism in a novel human adenovirus that causes epidemic keratoconjunctivitis. PLoS One. 2009;4:e5635. Markotter W, editor.
   PubMed Web of Science ®Google Scholar
• Robinson CM, Singh G, Lee JY, et al. Molecular evolution of human adenoviruses. Scientific Reports; 2013. p. 3.
   Google Scholar
• Han G, Niu H, Zhao S, et al. Identification and typing of respiratory adenoviruses in Guangzhou, Southern China using a rapid and simple method. Virol Sin. 2013;28:103–108.
   PubMedGoogle Scholar
• Blacklock J. Discussion on adenovirus infections. Proceedings of the Royal Society of Medicine. Birmingham Children’s Hospital, Birmingham, UK. 1957. Vol. 50. p. 753–760.
   Google Scholar
• Ginsberg HS. Newer aspects of adenovirus infections. Am J Public Health Nations Health. 1959;49:1480–1485.
   PubMed Web of Science ®Google Scholar
• Smith A. The adenoviruses. J Am Med Assoc. 1957;163:40.
   Web of Science ®Google Scholar
• Enders JF, Bell JA, Dingle JH, et al. “Adenoviruses”: group name proposed for new respiratory-tract viruses. Science. 1956;124:119–120.
   PubMed Web of Science ®Google Scholar
• Jawetz E, Kimura S, Nicholas AN, et al. New Type of APC virus from epidemic keratoconjunctivitis. Science. 1955;122:1190–1191.
   PubMed Web of Science ®Google Scholar
• Ormsby H, Fowle A, Doane F. Canadian cases of adenovirus infection 1951–1956. Am J Ophthalmol. 1957;43:17–20.
   PubMed Web of Science ®Google Scholar
• Huebner R, Rowe W. Adenoviruses as etiologic agents in conjunctivitis and keratoconjunctivitis. Am J Ophthalmol. 1957;43:20–25.
   PubMed Web of Science ®Google Scholar
• Veen JV D, Kok G. Isolation and typing of adenoviruses recovered from military recruits with acute respiratory disease in The Netherlands. Am J Epidemiol. 1957;65:119–129.
   Google Scholar
• Potter CW, Shedden WIH. The distribution of adenovirus antibodies in normal children. Epidemiol Infect. 1963;61:155–160.
   Google Scholar
• Joncas J, Moisan A, Pavilanis V. Incidence of Adenovirus Infection. Can Med Assoc J. 1962;87:52–58.
   PubMed Web of Science ®Google Scholar
• Tai F-H, Grayston JT. Adenovirus neutralizing antibodies in persons on Taiwan. Exp Biol Med. 1962;109:881–884.
   Web of Science ®Google Scholar
• Ritova VV, Zhdanov VM, Schastnv EI. Serological evidence of respiratory virus infections in Moscow children, 1948 to 1956. Pediatrics. 1966;38:402–404.
   PubMed Web of Science ®Google Scholar
• Hildes JA, Wilt JC, Stanfield FJ. Antibodies to adenovirus and to psittacosis in eastern arctic eskimos. Canadian J Public Health/Revue Canadienne de Santé Publique. 1958;49:230–231.
   Google Scholar
• Sterner G, Svartz‐Malmberg G. Adenovirus neutralizing antibodies in swedish children. Acta Paediatrica. 1962;51:617–620.
   PubMed Web of Science ®Google Scholar
• Kasel JA, Evans HE, Spickard A, et al. Conjunctivitis and enteric infection with adenovirus types 26 and 27: responses to primary, secondary and reciprocal cross-challenges. Transactions of the Association of American Physicians. 1962;75:179–189.
   Google Scholar
• Devi KI. Adenovirus infections in Delhi: isolation from tonsils and a serological survey. Indian J Med Res. 1968;56:20–26.
   PubMed Web of Science ®Google Scholar
• Afshar A, Abdi H, Hatami-Monazah H. The occurrence of adenovirus precipitating antibodies in human sera in Iran. Archives of Razi Institute. 1969;21:107–110.
   Google Scholar
• Evans AS, Jeffrey C, Niederman JC. The risk of acute respiratory infections in two groups of young adults in colombia, south america: a prospective seroepidemiologic study. Am J Epidemiol. 1971;93:463–471.
   PubMed Web of Science ®Google Scholar
• Brandt CD, Kim HW, Vargosko AJ, et al. Infections in 18, 000 infants and children in a controlled study of respiratory tract diseaseI. Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am J Epidemiol. 1969;90:484–500.
   PubMed Web of Science ®Google Scholar
• Trentin JJ, Yabe Y, Taylor G. The Quest for Human Cancer Viruses: A new approach to an old problem reveals cancer induction in hamsters by human adenovirus. Science. 1962;137:835–841.
   PubMed Web of Science ®Google Scholar
• Commission on Acute Respiratory Diseases. Acute respiratory disease among new recruits. Am J Public Health Nations Health. 1946;36:439–450.
   Web of Science ®Google Scholar
• Hilleman MR. Epidemiology of adenovirus respiratory infections in military recruit populations. Ann N Y Acad Sci. 1957;67:262–272.
   PubMed Web of Science ®Google Scholar
• Dingle JH, Langmuir AD. Epidemiology of acute respiratory disease in military recruits. Amer Rev Respir Dis. 1968;97(6).
   Google Scholar
• Sanchez JL, Cooper MJ, Myers CA, et al. Respiratory infections in the U.S. military: recent experience and control. Clin Microbiol Rev. 2015;28:743–800.
   PubMed Web of Science ®Google Scholar
• Weaver EA. Vaccines within vaccines. Hum Vaccin Immunother. 2014;10:544–556.
   PubMed Web of Science ®Google Scholar
• Collis PB, Dudding BA, Winter PE, et al. Adenovirus vaccines in military recruit populations: a cost-benefit analysis. J Infect Dis. 1973;128:745–752.
   PubMed Web of Science ®Google Scholar
• Šnejdarová V, Vonka V, Kutinová L, et al. The nature of adenovirus persistence in human adenoid vegetations. Arch Virol. 1975;48:347–357.
   PubMed Web of Science ®Google Scholar
• Winnacker E-L. Adenovirus DNA: structure and function of a novel replicon. Cell. 1978;14:761–773.
   PubMed Web of Science ®Google Scholar
• Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. BioTechniques. 1988;6:616–629.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio E, Del Grosso N, Chicca A, et al. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J Hyg (Lond). 1982;89:155–161.
   PubMedGoogle Scholar
• Taylor PE. Adenoviruses: diagnosis of infections. In: Kurstak E, Kurstak C, editors. Comparative diagnosis of viral diseases. Vol. 1. New York: Academic Press; 1977. p. 85.
   Google Scholar
• Schmttz H, Wigand R, Heinrich W. Worlwide epidemiology of human adenovirus infections. Am J Epidemiol. 1983;117:455–466.
   PubMed Web of Science ®Google Scholar
• Richmond S, Caul EO, Dunn SM, et al. An outbreak of gastroenteritis in young children caused by adenoviruses. Lancet. 1979;313:1178–1180.
   Google Scholar
• Uhnoo I, Wadell G, Svensson L, et al. Two new serotypes of enteric adenovirus causing infantile diarrhoea. Dev Biol Stand. 1983;53:311–318.
   PubMedGoogle Scholar
• Kidd AH, Madeley CR. In vitro growth of some fastidious adenoviruses from stool specimens. J Clin Pathol. 1981;34:213–216.
   PubMed Web of Science ®Google Scholar
• Avoort H VD, Ag W, Zomerdijk T, et al. Characterization of fastidious adenovirus types 40 and 41 by DNA restriction enzyme analysis and by neutralizing monoclonal antibodies. Virus Res. 1989;12:139–157.
   PubMed Web of Science ®Google Scholar
• Kidd AH. Genome variants of adenovirus 41 (subgroup G) from children with diarrhoea in South Africa. J Med Virol. 1984;14:49–59.
   PubMed Web of Science ®Google Scholar
• Uhnoo I, Wadell G, Svensson L, et al. Importance of enteric adenoviruses 40 and 41 in acute gastroenteritis in infants and young children. J Clin Microbiol. 1984;20:365–372.
   PubMed Web of Science ®Google Scholar
• Herrmann JE, Blacklow NR, Perron-Henry DM, et al. Incidence of enteric adenoviruses among children in Thailand and the significance of these viruses in gastroenteritis. J Clin Microbiol. 1988;26:1783–1786.
   PubMed Web of Science ®Google Scholar
• Oker-Blom N, Wager O, Strandstrom H, et al. Adenoviruses associated with pharyngoconjunctival fever; isolation of adenovirus type 7 & serological studies suggesting its etiological role in an epidemic in Helsinki. Ann Med Exp Biol Fenn. 1957;35:342–351.
   PubMedGoogle Scholar
• Wadell G, Jong JCD, Wolontis S. Molecular epidemiology of adenoviruses: alternating appearance of two different genome types of adenovirus 7 during epidemic outbreaks in Europe from 1958 to 1980. Infect Immun. 1981;34:368–372.
   PubMed Web of Science ®Google Scholar
• Wadell G, Cooney MK, Da Costa Linhares A, et al. Molecular epidemiology of adenoviruses: global distribution of adenovirus 7 genome types. J Clin Microbiol. 1985;21:403–408.
   PubMed Web of Science ®Google Scholar
• Chin J. Global estimates of AIDS cases and HIV infections: 1990. Aids. 1990;4:S277.
   PubMedGoogle Scholar
• Grohmann GS, Glass RI, Pereira HG, et al. Enteric viruses and diarrhea in HIV-infected patients. N Engl J Med. 1993;329:14–20.
   PubMed Web of Science ®Google Scholar
• Janoff EN, Orenstein JM, Manischewitz JF, et al. Adenovirus colitis in the acquired immunodeficiency syndrome. Gastroenterology. 1991;100:976–979.
   PubMed Web of Science ®Google Scholar
• Anders KH, Park C-S, Cornford ME, et al. Adenovirus encephalitis and widespread ependymitis in a child with AIDS. PNE. 1990;16:316–320.
   Google Scholar
• Krilov LR, Rubin LG, Frogel M, et al. Disseminated adenovirus infection with hepatic necrosis in patients with human immunodeficiency virus infection and other immunodeficiency states. Rev Infect Dis. 1990;12:303–307.
   PubMedGoogle Scholar
• Chastel C, Plantin P, Chomel JJ, et al. Respiratory tract infection caused by adenovirus 37 in an HIV-1 infected patient. Presse Med. 1990;19:1372.
   PubMed Web of Science ®Google Scholar
• Khoo SH, Bailey AS, de Jong JC, et al. Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology. J Infect Dis. 1995;172:629–637.
   PubMed Web of Science ®Google Scholar
• Varki NM, Bhuta S, Drake T, et al. Adenovirus hepatitis in two successive liver transplants in a child. Arch Pathol Lab Med. 1990;114:106–109.
   PubMed Web of Science ®Google Scholar
• Gooding LR, Wold WS. Molecular mechanisms by which adenoviruses counteract antiviral immune defenses. Crit Rev Immunol. 1990;10:53–71.
   PubMed Web of Science ®Google Scholar
• Graham FL. Adenoviruses as expression vectors and recombinant vaccines. Trends Biotechnol. 1990;8:85–87.
   PubMed Web of Science ®Google Scholar
• Imler J-L. Adenovirus vectors as recombinant viral vaccines. Vaccine. 1995;13:1143–1151.
   PubMed Web of Science ®Google Scholar
• Rosenfeld MA, Siegfried W, Yoshimura K, et al. Adenovirus-mediated transfer of a recombinant aol-Antitrypsin gene to the lung epithefium in vivo. Reports Science. 1991;252:431–434.
   Google Scholar
• Zabner J, Couture LA, Gregory RJ, et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell. 1993;75:207–216.
   PubMed Web of Science ®Google Scholar
• Brody SL, Crystal RG. Adenovirus-mediated in vivo gene transfer. Ann N Y Acad Sci. 1994;716:90–103.
   PubMed Web of Science ®Google Scholar
• Zuckerman JB, Robinson CB, Ks M, et al. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther. 1999;10:2973–2985.
   PubMed Web of Science ®Google Scholar
• Crystal RG. Adenovirus: the first effective in vivo gene delivery vector. Hum Gene Ther. 2014;25:3–11.
   PubMed Web of Science ®Google Scholar
• WHO meeting, 1989 Jun 19-22. Potential use of live viral and bacterial vectors for vaccines Report No.: Vaccine; 1990. Geneva.Vol. 8. p. 425–436.
   Google Scholar
• Zhang C, Zhou D. Adenoviral vector-based strategies against infectious disease and cancer. Hum Vaccin Immunother. 2016;12:2064–2074.
   PubMed Web of Science ®Google Scholar
• Modermott MR, Graham FL, Hanke T, et al. Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing hsv glycoprotein B. Virology. 1989;169:244–247.
   PubMed Web of Science ®Google Scholar
• Jönsson F, Kreppel F. Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5. Virus Genes. 2017;53:692–699.
   PubMed Web of Science ®Google Scholar
• Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol. 1999;10:440–447.
   PubMed Web of Science ®Google Scholar
• Abbink P, Lemckert AAC, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81:4654–4663.
   PubMed Web of Science ®Google Scholar
• Perreau M, Mennechet F, Serratrice N, et al. Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol. 2007;81:3272–3284.
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–1893.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Marovich MA, Dieffenbach CW, et al. Immune activation with HIV vaccines: implications of the adenovirus vector experience. Science. 2014;344:49–51.
   PubMed Web of Science ®Google Scholar
• Mennechet FJ, Tran TTP, Eichholz K, et al. Ebola virus vaccine: benefit and risks of adenovirus-based vectors. Expert Rev Vaccines. 2015;14:1471–1478.
   PubMed Web of Science ®Google Scholar
• Eichholz K, Bru T, Tran TTP, et al. Immune-complexed adenovirus induce AIM2-mediated pyroptosis in human dendritic cells. PLOS Pathogens. 2016;12:e1005871. Benedict CA, editor
   PubMed Web of Science ®Google Scholar
• Benlahrech A, Harris J, Meiser A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A. 2009;106:19940–19945.
   PubMed Web of Science ®Google Scholar
• Hu H, Eller MA, Zafar S, et al. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. Proc Natl Acad Sci U S A. 2014;111:13439–13444.
   PubMed Web of Science ®Google Scholar
• Frahm N, DeCamp AC, Friedrich DP, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest. 2012;122:359–367.
   PubMed Web of Science ®Google Scholar
• Perreau M, Kreemer EJ. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol. 2005;79:14595–14605.
   PubMed Web of Science ®Google Scholar
• Tran TTP, Eichholz K, Amelio P, et al. Humoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cells. PLoS Pathog. 2018 Aug;14(8):e1007127.
   Web of Science ®Google Scholar
• Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80:148–158.
   PubMed Web of Science ®Google Scholar
• Klonjkowski B, Gilardi-Hebenstreit P, Hadchouel J, et al. A recombinant E1-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo. Hum Gene Ther. 1997;8:2103–2115.
   PubMed Web of Science ®Google Scholar
• Michael NL. Rare serotype adenoviral vectors for HIV vaccine development. J Clin Invest. 2012;122:25–27.
   PubMed Web of Science ®Google Scholar
• Vitelli A, Folgori A, Scarselli E, et al. Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane. Expert Rev Vaccines. 2017;16:1241–1252.
   PubMed Web of Science ®Google Scholar
• Abbink P, Kirilova M, Boyd M, et al. Rapid cloning of novel rhesus adenoviral vaccine vectors. J Virol. 2018;92(6):e01924-17.
   Web of Science ®Google Scholar
• Hoppe E, Pauly M, Gillespie TR, et al. Multiple Cross-Species Transmission Events of Human Adenoviruses (HAdV) during Hominine Evolution. Mol Biol Evol. 2015;32:2072–2084.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector ebola vaccine. N Engl J Med. 2017;376:928–938.
   PubMed Web of Science ®Google Scholar
• Chiu CY, Yagi S, Lu X, et al. A novel adenovirus species associated with an acute respiratory outbreak in a baboon colony and evidence of coincident human infection. mBio. 2013;4(2):e00084-13.
   Web of Science ®Google Scholar
• Lee JY, Lee JS, Materne EC, et al. Bacterial RecA protein promotes adenoviral recombination during in vitro infection. mSphere. 2018;3. Greber UF, editor.
   Web of Science ®Google Scholar
• Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007—an update. J Gene Med. 2007;9:833–842.
   PubMed Web of Science ®Google Scholar
• Lemckert AAC. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol. 2006;87:2891–2899.
   PubMed Web of Science ®Google Scholar
• Li Q, Liu Q, Huang W, et al. Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines. Human Vaccines & Immunotherapeutics. 2017;13(6):1433–1440.
   PubMed Web of Science ®Google Scholar
• Yu B, Zhou Y, Wu H, et al. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. J Med Virol. 2012;84:1408–1414.
   PubMed Web of Science ®Google Scholar
• Piedra PA, Poveda GA, Ramsey B, et al. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics. 1998;101:1013–1019.
   PubMed Web of Science ®Google Scholar
• Jian L, Zhao Q, Zhang S, et al. The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China. Arch Virol. 2014;159:465–470.
   PubMed Web of Science ®Google Scholar
• Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010;28:950–957.
   PubMed Web of Science ®Google Scholar
• Zhang S, Huang W, Zhou X, et al. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J Med Virol. 2013;85:1077–1084.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Kik SV, Weverling GJ, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011;29:5203–5209.
   PubMed Web of Science ®Google Scholar
• Sumida SM, Truitt DM, Lemckert AAC, et al. neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005;174:7179–7185.
   PubMed Web of Science ®Google Scholar
• Kostense S, Koudstaal W, Sprangers M, et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. Aids. 2004;18:1213–1216.
   PubMed Web of Science ®Google Scholar
• Holterman L, Vogels R, van der Vlugt R, et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol. 2004;78:13207–13215.
   PubMed Web of Science ®Google Scholar
• Duffy MR, Alonso-Padilla J, John L, et al. Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56. J Gen Virol. 2018;99:135–147.
   PubMed Web of Science ®Google Scholar
• Vogels R, Zuijdgeest D, van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003;77:8263–8271.
   PubMed Web of Science ®Google Scholar
• Yamadera S, Yamashita K, Akatsuka M, et al. Trend of adenovirus type 7 infection, an emerging disease in Japan. Jjmsb. 1998;51:43–51.
   Google Scholar
• Noda M, Yoshida T, Sakaguchi T, et al. Molecular and epidemiological analyses of human adenovirus type 7 strains isolated from the 1995 nationwide outbreak in Japan. J Clin Microbiol. 2002;40:140–145.
   PubMed Web of Science ®Google Scholar
• Miwa C. [Serosurvey for adenovirus type 3 and adenovirus type 7 infection in resident in Gifu Prefecture, 1996]. Kansenshogaku Zasshi. 1997;71:1261–1262.
   PubMedGoogle Scholar
• Kajiwara J, Hamasaki M, Ishibashi T, et al. [Analysis of genome types of adenovirus type 7 isolated in Fukuoka Prefecture in 1996]. Kansenshogaku Zasshi. 1997;71:895–898.
   PubMedGoogle Scholar
• Su X, Tian X, Jiang Z, et al. Human adenovirus serotype 3 vector packaged by a rare serotype 14 hexon. PLoS One. 2016;11:e0156984. Ulasov I, editor
   PubMed Web of Science ®Google Scholar
• Lyons A, Longfield J, Kuschner R, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine. 2008;26:2890–2898.
   PubMed Web of Science ®Google Scholar
• Yang W-X, Zou X-H, Jiang S-Y, et al. Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions. Vaccine. 2016;34:5579–5586.
   PubMed Web of Science ®Google Scholar
• Kahl CA, Bonnell J, Hiriyanna S, et al. Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine. 2010;28:5691–5702.
   PubMed Web of Science ®Google Scholar
• Wang X, Xing M, Zhang C, et al. Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China. Emerg Microbes Infect. 2014;3:e30–e30.
   PubMed Web of Science ®Google Scholar
• Ewer KJ, Lambe T, Rollier CS, et al. Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol. 2016;41:47–54.
   PubMed Web of Science ®Google Scholar
• Croyle MA, Patel A, Tran KN, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One. 2008;3:e3548. Doolan DL, editor
   PubMed Web of Science ®Google Scholar
• Katz S, Jordan WS Jr., Badger GF, et al. Studies of complement-fixing and neutralizing antibodies against certain adenoviruses. J Immunol. 1957;78:118–121.
   Google Scholar
• Seiradake E, Henaff D, Wodrich H, et al. The cell adhesion molecule “CAR” and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog. 2009;5:e1000277.
   PubMed Web of Science ®Google Scholar
• Sprangers MC, Lakhai W, Koudstaal W, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003;41:5046–5052.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Li Y, Cun A, et al. Chimpanzee adenovirus antibodies in humans, Sub-Saharan Africa. Emerg Infect Dis. 2006;12:1596–1599.
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Tominaga K, Kikukawa M, et al. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. Anticancer Res. 1998;18:2345–2351.
   PubMed Web of Science ®Google Scholar
• Aste-Amézaga M, Bett AJ, Wang F, et al. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther. 2004;15:293–304.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Pau MG, Custers JHHV, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 Immunity. J Immunol. 2004;172:6290–6297.
   PubMed Web of Science ®Google Scholar
• Kremer EJ. Van de Perre P. Ebola vaccines based on adenovirus vectors and risk of HIV. BMJ. 2015;350:h1307–h1307.
   PubMedGoogle Scholar
• Kennedy SB, Bolay F, Kieh M, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017;377:1438–1447.
   PubMed Web of Science ®Google Scholar
• Venkatraman N, Anagnostou N, Bliss C, et al. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-MTM. Vaccine. 2017;35:6208–6217.
   PubMed Web of Science ®Google Scholar
• Afolabi MO, Tiono AB, Adetifa UJ, et al. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Mol Ther. 2016;24:1470–1477.
   PubMed Web of Science ®Google Scholar
• Hayton E-J, Rose A, Ibrahimsa U, et al. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One. 2014 Jul;9(7):e101591.
   Web of Science ®Google Scholar
• Morris SJ, Sebastian S, Spencer AJ, et al. Simian adenoviruses as vaccine vectors. Future Virol. 2016;11:649–659.
   PubMed Web of Science ®Google Scholar
• Dudareva M, Andrews L, Gilbert SC, et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan Children, in the context of vaccine vector efficacy. Vaccine. 2009;27:3501–3504.
   PubMed Web of Science ®Google Scholar
• Ersching J, Hernandez MIM, Cezarotto FS, et al. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology. 2010;407:1–6.
   PubMed Web of Science ®Google Scholar
• Cook J, Radke J. Mechanisms of pathogenesis of emerging adenoviruses. F1000 Research. 2017;6(F1000 Faculty Rev):90. Last updated: 30 Jan 2017.
   Google Scholar
• Anchim A, Raddi N, Zig L, et al. Humoral responses elicited by adenovirus displaying epitopes are induced independently of the infection process and shaped by the toll-like receptor/myd88 pathway. Front Immunol. 2018 Feb;9:Article 124.
   PubMed Web of Science ®Google Scholar
• Eichholz K, Mennechet FJD, Kremer EJ. Human coagulation factor X-adenovirus type 5 complexes poorly stimulate an innate immune response in human mononuclear phagocytes. J Virol. 2014;89:2884–2891.
   PubMed Web of Science ®Google Scholar
• Perreau M, Welles HC, Pellaton C, et al. The number of toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes. J Virol. 2012;86:6279–6285.
   PubMed Web of Science ®Google Scholar
• Hagedorn C, Kreppel F. Capsid engineering of adenovirus vectors: overcoming early vector–host interactions for therapy. Hum Gene Ther. 2017;28:820–832.
   PubMed Web of Science ®Google Scholar
• Ladner JT, Grubaugh ND, Pybus OG, et al. Precision epidemiology for infectious disease control. Nat Med. 2019;25:206–211.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Su X, Seto D, et al. Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine. 2009;27:1145–1153.
   PubMed Web of Science ®Google Scholar
• Binn LN, Sanchez JL, Gaydos JC. Emergence of adenovirus type 14 in US military recruits - a new challenge. J Infect Dis. 2007;196:1436–1437.
   PubMed Web of Science ®Google Scholar
• Colloca S, Folgori A, Ammendola V, et al. Generation and screening of a large collection of novel simian Adenovirus allows the identification of vaccine vectors inducing potent cellular immunity in humans: a range of novel simian adenoviral vectors, which are capable of priming high levels of T cell responses in man, has been defined. Sci Transl Med. 2012;4(115):115ra2.
   PubMed Web of Science ®Google Scholar
• Emini E, Shiver J, Bett A, et al. Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby. GooglePatents. 2004; EP1611237A1.
   Google Scholar
• Lu ZZ, Zou XH, Dong LX, et al. Novel recombinant adenovirus type 41 vector and its biological properties. J Gene Med. 2009;11:128–138.
   PubMed Web of Science ®Google Scholar
• Lu ZZ, Zou XH, Lastinger K, et al. Enhanced growth of recombinant human adenovirus type 41 (HAdV-41) carrying ADP gene. Virus Res. 2013;176:61–68.
   PubMed Web of Science ®Google Scholar
• Lubeck MD, Davis AR, Chengalvala M, et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci USA. 1989;86:6763–6767.
   PubMed Web of Science ®Google Scholar
• Hsu KH, Lubeck MD, Davis AR, et al. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J Infect Dis. 1992;166:769–775.
   PubMed Web of Science ®Google Scholar
• Lemiale F, Haddada H, Nabel GJ, et al. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine. 2007;25:2074–2084.
   PubMed Web of Science ®Google Scholar
• Hofmayer S, Madisch I, Darr S, et al. Unique sequence features of the Human Adenovirus 31 complete genomic sequence are conserved in clinical isolates. BMC Genomics. 2009;10:557.
   PubMed Web of Science ®Google Scholar
• Sakurai F, Kawabata K, Mizuguchi H, et al. Adenovirus vectors composed of subgroup B adenoviruses. Curr Gene Ther. 2007;7:229–238.
   PubMed Web of Science ®Google Scholar
• Omosa-Manyonyi G, Mpendo J, Ruzagira E, et al. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. PLoS One. 2015; 10(5):e0125954.
   PubMed Web of Science ®Google Scholar
• Ouédraogo A, Tiono AB, Kargougou D, et al. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One. 2013;8(11):e78679.
   PubMed Web of Science ®Google Scholar
• Abrahamsen K, Kong HL, Mastrangeli A, et al. Construction of an adenovirus type 7a E1A- vector. J. Virol. 1997;71:8946–8951.
   PubMed Web of Science ®Google Scholar
• Lemckert AA, Sumida SM, Holterman L, et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol. 2005;79:9694–9701.
   PubMed Web of Science ®Google Scholar
• Garnett CT, Erdman D, Xu W, et al. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol. 2002;76:10608–10616.
   PubMed Web of Science ®Google Scholar
• Wurzel DF, Mackay IM, Marchant JM, et al. Adenovirus species C is associated with chronic suppurative lung diseases in children. Clin Infect Dis.2014;59:34–40.
   Google Scholar
• Lhomme E, Richert L, Moodie Z, et al. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. PLoS One. 2016;11(4):e0152952.
   PubMed Web of Science ®Google Scholar
• Kaulfuß M, Wensing I, Windmann S, et al. Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery. Retrovirology. 2017;14:8.
   PubMed Web of Science ®Google Scholar
• Fonseca JA, Cabrera-Mora M, Kashentseva EA, et al. A Plasmodium Promiscuous T Cell Epitope Delivered within the HAdV-C5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine. PLoS One. 2016;11:e0154819.
   PubMed Web of Science ®Google Scholar
• Li X, Huang J, Zhang M, et al. Human CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice. Vaccine. 2016;34:4501–4506.
   PubMed Web of Science ®Google Scholar
• McGuire KA, Miura K, Wiethoff CM, et al. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission. Malar J. 2017;16:254.
   PubMed Web of Science ®Google Scholar
• Li JX, Hou LH, Meng FY, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017;5:e324–e334.
   Google Scholar
• Dolzhikova IV, Zubkova OV, Tukhvatulin AI, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother.2017;13:613–620.
   Google Scholar
• Wang L, Liu J, Kong Y, et al. Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice. Hum Gene Ther.2018;29:87–95.
   Google Scholar
• Wu L, Zhang Z, Gao H, et al. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Hum Vaccin Immunother.2017;13:2078–2085.
   Google Scholar
• Zhu FC, Wurie AH, Hou LH, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017;389:621–628.
   PubMed Web of Science ®Google Scholar
• Van Kampen KR, Shi Z, Gao P, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2015;23:1029–1036.
   Google Scholar
• Shen CF, Jacob D, Zhu T, et al. Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate. Vaccine. 2016;34:3381–3387.
   PubMed Web of Science ®Google Scholar
• Smaill F, Jeyanathan M, Smieja M, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med. 2013;5:205ra134.
   PubMed Web of Science ®Google Scholar
• Guo Q, Chan JF, Poon VK, et al. Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models. J. Infect. Dis. 2018;218:365–377.
   PubMed Web of Science ®Google Scholar
• Kim E, Erdos G, Huang S, et al. Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation. EBioMedicine. 2016;13:315–320.
   PubMed Web of Science ®Google Scholar
• Chen S, Xu Q, Zeng M. Oral vaccination with an adenovirus-vectored vaccine protects against botulism. Vaccine.2013;31:1009–1011.
   Google Scholar
• Xie Y, Gao P, Li Z, et al. A Recombinant Adenovirus Expressing P12A and 3C Protein of the Type O Foot-and-Mouth Disease Virus Stimulates Systemic and Mucosal Immune Responses in Mice. Biomed Res Int. 2016;2016:7849203.
   PubMedGoogle Scholar
• Jung SY, Kang KW, Lee EY, et al. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine. 2018;36:3468–3476.
   PubMed Web of Science ®Google Scholar
• Guo X, Deng Y, Chen H, et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology. 2015;145:476–484.
   PubMed Web of Science ®Google Scholar
• Vos A, Neubert A, Pommerening E, et al. Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. J Gen Virol. 2001;82:2191–2197.
   PubMed Web of Science ®Google Scholar
• Xiang ZQ, Greenberg L, Ertl HC, et al. Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology. 2014;450-451:243–249.
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Wang D, Ewing D, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol. 2008;82:6927–6934.
   PubMed Web of Science ®Google Scholar
• Feng Y, Li C, Hu P, et al. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques. Emerg Microbes Infect. 2018;7:101.
   PubMed Web of Science ®Google Scholar
• Capone S, Meola A, Ercole BB, et al. A novel adenovirus Type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol. 2006;80:1688–1699.
   PubMed Web of Science ®Google Scholar
• Crosby CM, Barry MA. IIIa deleted adenovirus as a single-cycle genome replicating vector. Virology. 2014;462-463:158–165.
   PubMed Web of Science ®Google Scholar
• Crosby CM, Matchett WE, Anguiano-Zarate SS, et al. Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses. J Virol. 2017;91(2):e00720–16.
   PubMed Web of Science ®Google Scholar
• Pauly M, Hoppe E, Mugisha L, et al. High prevalence and diversity of species D adenoviruses (HAdV-D) in human populations of four Sub-Saharan countries. Virol J. 2014;11:25.
   PubMed Web of Science ®Google Scholar
• Andersson EK, Mei YF, Wadell G. Adenovirus interactions with CD46 on transgenic mouse erythrocytes. Virology. 2010;402:20–25.
   PubMed Web of Science ®Google Scholar
• Nilsson EC, Storm RJ, Bauer J, et al. The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis. Nat Med. 2011;17:105–109.
   PubMed Web of Science ®Google Scholar
• Milligan ID, Gibani MM, Sewell R, et al. Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA. 2016;315:1610–1623.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Liu J, Peter L, et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis. 2013;207:248–256.
   PubMed Web of Science ®Google Scholar
• Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4:115ra2.
   PubMed Web of Science ®Google Scholar
• Johnson MJ, Björkström NK, Petrovas C, et al. Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression. Vaccine. 2014;32:717–724.
   PubMed Web of Science ®Google Scholar
• Belousova N, Mikheeva G, Xiong C, et al. Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43. Oncotarget. 2016;7:53414–53429.
   PubMedGoogle Scholar
• Farrow AL, Peng BJ, Gu L, et al. A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors. Viruses. 2016;8:78.
   PubMed Web of Science ®Google Scholar
• Weaver EA, Barry MA. Low seroprevalent species D adenovirus vectors as influenza vaccines. PLoS One. 2013;8:e73313.
   PubMed Web of Science ®Google Scholar
• Thorner AR, Lemckert AA, Goudsmit J, et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J Virol. 2006;80:12009–12016.
   PubMed Web of Science ®Google Scholar
• Lapuente D, Ruzsics Z, Thirion C, et al. Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses. Vaccine. 2018;36:2712–2720.
   PubMed Web of Science ®Google Scholar
• Zhou X, Robinson CM, Rajaiya J, et al. Analysis of human adenovirus type 19 associated with epidemic keratoconjunctivitis and its reclassification as adenovirus type 64. Invest Ophthalmol Vis Sci. 2012;53:2804–2811.
   PubMed Web of Science ®Google Scholar
• Gray GC, Callahan JD, Hawksworth AW, et al. Respiratory diseases among U.S. military personnel: countering emerging threats. Emerg Infect Dis. 1999;5:379–385.
   PubMed Web of Science ®Google Scholar
• Khurana S, Coyle EM, Manischewitz J, et al. Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization. PLoS One. 2015;10:e0115476.
   PubMed Web of Science ®Google Scholar
• Gurwith M, Lock M, Taylor EM, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis. 2013;13:238–250.
   PubMed Web of Science ®Google Scholar
• Alexander J, Ward S, Mendy J, et al. Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS One. 2012;7:e31177.
   PubMed Web of Science ®Google Scholar
• Christensen ML. Human viral gastroenteritis. Clin Microbiol Rev. 1989;2:51–89.
   PubMed Web of Science ®Google Scholar
• Yamasaki, S., et al. A single intraduodenal administration of human adenovirus 40 vaccine effectively prevents anaphylactic shock. Clin Vaccine Immunol. 2013;20:1508–1516.
   PubMed Web of Science ®Google Scholar
• Lenman, A, Liaci AM, Liu Y, et al. Polysialic acid is a cellular receptor for human adenovirus 52. Proc Natl Acad Sci U S A. 2018 May 1;115(8):E4264–E4273.
   PubMed Web of Science ®Google Scholar